# Closed automated cell-therapy manufacturing

Source: https://onco.cc/technologies/closed-automated-cell-manufacturing/  
OnCo record `closed-automated-cell-manufacturing` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sealed, robot-run machines that turn a patient's blood cells into a CAR-T product with far fewer hands, clean rooms, and mistakes.

## Summary

Functionally closed, GMP-in-a-box platforms (Miltenyi CliniMACS Prodigy, Lonza Cocoon, Cellares Cell Shuttle, Cytiva Sefia) integrate cell selection, activation, transduction, expansion, and harvest in single-use cassettes. They cut labour and clean-room grade requirements, shorten vein-to-vein time, and are the prerequisite for point-of-care and decentralised manufacturing. Throughput per unit and comparability across sites remain the constraints.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-09-08
- Tags: supporting
- Principle: Single-use fluid paths with integrated centrifugation, magnetic selection, incubation, and sensors; process recipes run automatically and log every step for batch release.
- Strengths: Fewer open manipulations and contamination events; Lower clean-room grade needed; Reproducible, software-logged processes
- Limitations: Capital cost per unit; Process comparability when moving between platforms; Still 7-14 days of culture for most products

## Sources

- FDA guidance: considerations for the development of CAR T cell products: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Cell-therapy release and potency testing](https://onco.cc/technologies/cell-therapy-release-testing/), [Flow cytometers](https://onco.cc/technologies/flow-cytometers/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/), [Point-of-care and decentralised cell manufacturing](https://onco.cc/technologies/point-of-care-cell-manufacturing/), [Single-use bioprocessing systems](https://onco.cc/technologies/single-use-bioprocessing/)
- companies: [Cellares](https://onco.cc/companies/cellares/), [Cytek Biosciences](https://onco.cc/companies/cytek-biosciences/), [Cytiva (Danaher)](https://onco.cc/companies/cytiva/), [Lonza](https://onco.cc/companies/lonza/), [Miltenyi Biotec](https://onco.cc/companies/miltenyi-biotec/), [Terumo Blood and Cell Technologies](https://onco.cc/companies/terumo-bct/)
- terms: [Vein-to-vein time and manufacturing slots](https://onco.cc/terms/vein-to-vein-time/)

---
JSON: https://onco.cc/api/v1/entities/closed-automated-cell-manufacturing.json